Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pixantrone (BBR 2778) in Patients With Refractory Acute Myelogenous Leukemia (AML)

This study has been completed.
Information provided by:
CTI BioPharma Identifier:
First received: March 28, 2005
Last updated: August 21, 2007
Last verified: August 2007
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Estimated Study Completion Date: March 2007
  Estimated Primary Completion Date: No date given